Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel together with bortezomib may kill more tumor cells

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Bortezomib; Docetaxel

Criteria

Criteria:

• No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or any other cancer for which the patient has been disease-free for 5 years.

• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

• Progressive or recurrent NSCLC after treatment with 1 prior platinum-based chemotherapy regimen for metastatic disease. Prior neoadjuvant/adjuvant chemotherapy and/or concurrent chemoradiation for early-stage disease allowed.

• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas) and recovered.

• No prior docetaxel or bortezomib

• Prior epidermal growth factor receptor inhibitor therapy allowed.

• Prior paclitaxel allowed

• At least 4 weeks since prior major surgery and recovered.

• At least 2 weeks since prior and no concurrent enzyme-inducing anticonvulsants.

• No concurrent hormonal therapy, biologic therapy, or radiotherapy to measurable lesions. Concurrent palliative radiotherapy to small-field nonindicator lesions (e.g., painful bony metastases) allowed.

• Measurable disease* with >= 1 unidimensionally objectively measurable lesion, including any of the following:

• Lung mass (measurable on chest x-ray, tomograms, or CT scan)

• Enlarged lymph nodes

• Liver metastasis (measurable as a discrete focal lesion on radionuclide or CT scan, or ultrasound)

• Metastatic abdominal mass (measurable on CT scan with >= 1 perpendicular diameter ≥ the distance between cuts)

• Measurable disease must be outside the previous radiation field or a new lesion must be present.

• Life expectancy >= 12 weeks

• Progressive disease within a previously radiated field allowed.

• [Note: *Measurable disease DOES NOT include bone metastases or non-focal liver metastases].

• No symptomatic or untreated brain metastasis requiring steroids. Asymptomatic, previously treated (surgical resection or radiotherapy) brain metastasis allowed provided they are neurologically stable and >= 4 weeks since prior steroids.

• Creatinine clearance >= 50 mL/min

• Creatinine =< 1.6 mg/dL

• Bilirubin normal

• AST =< 2 times upper limit of normal

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No peripheral neuropathy >= grade 2

• Absolute granulocyte count >= 1,500/mm³

• Platelet count >= 100,000/mm³

• Cutaneous nodule

• ECOG performance status 0-1

• At least 4 weeks since prior radiotherapy and recovered.